Collaborative Arrangement, Rights And Obligations, Cash Consideration, Value

No definition available.

Name:	prme_CollaborativeArrangementRightsAndObligationsCashConsiderationValue
Namespace Prefix:	prme_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Liability, Value

+ References

No definition available.

+ Details

Name:	prme_CollaborativeArrangementRightsAndObligationsLiabilityValue
Namespace Prefix:	prme_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Remaining Performance Obligation

+ References

No definition available.

+ Details

Name:	prme_CollaborativeArrangementRightsAndObligationsRemainingPerformanceObligation
Namespace Prefix:	prme_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Stock Consideration, Value

+ References

No definition available.

+ Details

Name:	prme_CollaborativeArrangementRightsAndObligationsStockConsiderationValue
Namespace Prefix:	prme_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Rights And Obligations, Upfront Payment

+ References

No definition available.

+ Details

Name:	prme_CollaborativeArrangementRightsAndObligationsUpfrontPayment
Namespace Prefix:	prme_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of Royalty Funding Received

+ References

No definition available.

+ Details

Name:	prme_RoyaltiesPaymentPercentageOfRoyaltyFundingReceived
Namespace Prefix:	prme_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=prme_JunoTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=prme_CollaborativeArrangementResearchCollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=prme_CysticFibrosisFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=prme_CollaborativeArrangementCysticFibrosisFoundationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements - Narrative (Details) - USD ($) $ in Millions	1 Months Ended
	Aug. 31, 2025	Jul. 31, 2025	Sep. 30, 2025	Dec. 31, 2024
Juno Therapeutics, Inc. \| Collaborative Arrangement, Research Collaboration and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied			$ 66.7
Cystic Fibrosis Foundation \| Collaborative Arrangement, Cystic Fibrosis Foundation Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment		$ 24.0
Received cash funding	$ 6.0
Equity investment	$ 6.0
Royalty funding received (in percent)		250.00%
Research funding liability		$ 6.0		$ 12.0